The Economic Times

From Jab to Pills: Novo Nordisk, Eli Lilly set to take obesity drug battle to India

Indias obesity drug market is set for a new phase as Novo Nordisks oral Wegovy and Eli Lillys oral GLP-1 orforglipron are expected to launch in the first half of 2027. Industry sources said both have been submitted to Indian regulators, potentially expanding demand beyond injectable treatments.